Regent Pacific (or the “Group”) is a Hong Kong-based investment company holding ground-breaking corporate and strategic investments focused on the healthcare and life sciences sectors.
The Group’s principal investment is Plethora Solutions Holdings plc (“Plethora”), a wholly-owned subsidiary. Plethora is a speciality pharmaceutical company that is focussed on the commercialisation of its product Fortacin™ - the first EU-approved topical prescription treatment for premature ejaculation – as its core product. Fortacin™ was commercially launched in the United Kingdom in November 2016, to be further rolled-out in Europe in early 2018. Discussions are ongoing with new potential commercial partners with regards to “out-licensing” Fortacin™ in other key markets including Asia Pacific, Middle East, Latin America, North America and sub-Sahara Africa.
In addition, the Group holds a stake in The Diabetic Boot Company Limited, a private UK medical device company that makes PulseflowDF™, an innovative diabetic foot ulcer treatment. PulseflowDF™ is on sale in the United Kingdom, and also the Veterans Administration Hospitals in the United States.
Regent Pacific has been listed on The Stock Exchange of Hong Kong Limited since May 1997. The company has a strong track record of investments and has returned approximately US$298 million to shareholders since its IPO.